Ironwood Pharmaceuticals, Inc.
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Find out what a historical investment in Ironwood Pharmaceuticals, Inc. would be worth today using our IRWD stock calculator.
$606.79M
-
0.00%
1
$3.76
$3.52
$0.00
$5.13
$0.53
Ready to start your investing journey with Stake?
Open an accountIRWD FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in IRWD
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in IRWD
on Stake
Buy IRWD from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of IRWD from only US$10 with fractional shares
